Hemostemix Inc. (TSX and OTCQB:TSX V:HEM; OTCQB:HMTXF)

1:30 PM - 1:45 PM, Wednesday, June 5, 2019 ・ Theater 2
Hemostemix (TSX V:HEM; OTCQB:HMTXF) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. Hemostemix’s proprietary platform technology is based on more than 10 years of clinical data demonstrating the ability of our autologous cell product to regenerate diseased and damaged tissue. Our efficient, scalable and cost-effective platform has the potential to generate therapies for a broad range of ischemic diseases. ACP-01, our lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is currently in a Phase 2 clinical trial in Canada and the United States.
Ticker:
TSX V:HEM; OTCQB:HMTXF
Exchange:
TSX and OTCQB
Company Type:
Company Website:
Company HQ State:
Alberta
Company HQ Country:
Canada
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
ACP-01
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President and Chief Medical Officer
Hemostemix Inc.